Market Size of France In-Vitro Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 7.50 % |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France In-Vitro Diagnostics Market Analysis
France In-Vitro Diagnostic Market is expected to witness a CAGR of 7.5% over the forecast period.
The emergence of the COVID-19 pandemic had a significant impact on France in-vitro diagnostic market owing to the factors such as delayed diagnostic tests and the scarcity of laboratory reagents to perform tests. For instance, as per the article published in March 2022 in PubMed, based on data from the French administrative healthcare database (SNDS) on the entire French population (67 million people), screening, diagnostic and therapeutic activity was monitored and compared the post-pandemic situation every month, and a significant decline in all activities was observed during the first lockdown in France. However, COVID-19 diagnostic tests were widely carried out during the pandemic, which was one of the factors that significantly affected the market growth. The market is anticipated to witness growth in the coming years due to the rise in chronic diseases and the increase in demand for early diagnosis and point of care.
Certain factors that are also propelling the market growth are the rising incidence of chronic diseases, increasing awareness and acceptance of personalized medicine and companion diagnostics, and the increasing use of point-of-care (POC) diagnostics. The rising burden of chronic diseases such as infectious diseases, cardiovascular diseases, cancers, and others is the main factor driving the demand for the in-vitro diagnostics market over the forecast period. For instance, according to the IDF Atlas 10th edition published in 2021, about 3,942.9 thousand people were living with diabetes in France in 2021. In addition, as per the same source, this number is projected to reach 4,184.9 thousand by 2030 and 4,225.7 thousand by 2045. Furthermore, the increasing use of point-of-care diagnostics in the country as well as initiatives taken to increase awareness and testing for chronic diseases, is also contributing to the growth of the market. For instance, In March 2022, France launched a new colon-cancer testing system for people aged 50-74 years.
Thus, due to the rise in chronic diseases, and the increase in invitro diagnostics product launches, the France in-vitro diagnostics market is anticipated to witness growth in the market over the forecast period. However, the stringent regulations related to diagnostic equipment and devices are impeding the market growth over the forecast period.